ArticleFrontiers in cell and developmental biology2025
Exosomal lncRNA XR_001793654.1 in human cardiac explant-derived alleviates atrial fibrillation via abolishing the miR-107-3p-mediated KLF13 inhibition.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is a type of arrhythmia that occurs in the upper part of the heart. Extracellular vesicles (EVs) released by human cardiac explant-derived cells (CDCs) contain bioactive cargos that may function as diagnostic indicators or therapeutic candidates for AF. The lncRNA XR_001793654.1 has been identified as a putative modulator in AF pathogenesis. Methods: Human CDCs were derived from left atrial appendages collected during cardiac surgery. Then, EVs were isolated from cultured CDCs using ultracentrifugation. XR_001793654.1 expression was quantified in EVs. The relationship between XR_001793654.1, miR-107-3p, and KLF13 was identified. Results: XR_001793654.1 was upregulated in EVs from human CDCs. Systemic delivery of these EVs Conclusion: In conclusion, human CDC-derived EV containing XR_001793654.1 alleviates atrial fibrosis and AF through neutralizing miR-107-3p-mediated downregulation of KLF13. These findings offer new perspectives on AF molecular mechanisms and emphasize XR_001793654.1 as a promising intervention target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.